Inventory: A selection of Lancet studies on October 24, 2020.

1. March-July 2020, USA SARS-CoV-2 Antibody Positive Rate Study DOI: https://doi.org/10.1016/S0140-6736 (2 0) 32009-2 People receiving dialysis are subject to routine monthly laboratory tests, and a serotypto-positive assessment of severe acute respiratory syndrome (SARS-Cov-2) in this population can help to arrive at more realistic, fair and repeatable results.
researchers received samples from approximately 1,300 dialysis facilities across the United States, and as of July 2020, the remaining plasma of 28,503 randomly selected adult dialysis patients was tested for spike protein-binding total antibody chemical luminescence (100% sensitivity, 99.8% specificity). the serum-positive rate of SARS-Cov-2 in the
sample was 8.0%, and the standard serum-positive rate was 8.3% for dialysis population in the United States and 9.3% for adult populations in the United States.
the U.S. dialysis population, the region with the lowest serotyt positive rate was in the West, at 3.5 percent, and in the Northeast, at 27.2 percent.
the sero-positive rate of 9.2 per 100,000 people, which is highly correlated with the number of deaths per 100,000 population (Spearman's ρ-0.77).
found that non-Hispanic blacks (OR=3.9), Hispanics (OR=2.3), population density (up to 1/5 vs lowest 1/5 region OR=10.3) and the implementation of blockades and restrictions on aggregation (or=0.4 in March vs July) all had a significant impact on virus-positive rates.
. -- Researchers recently reported the results of a randomized trial to assess the prognostic effects of Lopinavi-Litonavi on Covid-19 hospitalized patients at https://doi.org/10.1016/S0140-6736 (20)32013-4.
the study was conducted at 176 health centres in the UK.
patients receive 400mg of lopinave-100mg litonave treatment or a placebo on a routine basis, 10 days a month or until discharge.
of the study was a 28-day mortality rate.
1,616 patients were treated with Lopinave-Litonave and 3,424 received routine care only.
28 days, 374 patients in the Lopinave-Litonave treatment group died, and 767 patients in the general care group (23% vs. 22%, RR s 1.03) were consistent among the subgroups.
between the two groups (both 11 days) and the survival rate within 29 days (RR-0.98).
for patients who did not receive mechanical airfly at the baseline, there was no significant difference in the compound end points of mechanical air rate and mortality between groups (RR=1.09).
. Preoperative iron therapy does not improve the need for postoperative blood transfusions in anemia patients DOI: https://doi.org/10.1016/S0140-6736 (20) 31539-7 The proportion of patients with anemia during preoperative examinations is high, and anemia is associated with poor postoperative prognosis.
recently examined the effects of preoperative iron therapy on reducing blood transfusion needs and patient prognosis in patients with anemia undergoing selected abdominal surgery.
prepare for abdominal surgery and are involved in adult participants who find anemia during preoperative examinations.
anaemia is defined as male hemoglobin below 130 g/L and female hemoglobin below 120 g/L.
patients received intravenous iron (1g of estred iron) or a placebo 10-42 days before surgery.
end point of the study was blood transfusion or death.
487 patients were involved in the study, including 243 in the placebo group, 244 in the intravenous group of ferro-maltose, and 474 (97%) in the patients.
67 (28%) of the 237 patients in the placebo group died or needed blood transfusions, and 69 of the 237 patients in the intravenous iron group (29%) died or needed blood transfusions (risk ratio 1.03).
105 patients in the placebo group received blood transfusions and 105 cases in the intravenous iron group (ratio 0.98).
significant differences in pre-specified safety endpoints between groups.
MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that state "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here.